Top Markets
Coin of the day
INOVIQ Ltd INOVIQ Ltd

INOVIQ Ltd

IIQ
Rank in Stocks #29959
INOVIQ Ltd specializes in the research, development, and commercialization of... INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Share Price
$0.13400411
Market Cap
$18.86M
Change (1 day)
2.70%
Change (1 year)
-48.10%
Country
AU
Trade INOVIQ Ltd (IIQ)

Category

P/S ratio for INOVIQ Ltd (IIQ)
P/S ratio as of 2026 TTM: 0
According to INOVIQ Ltd latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for INOVIQ Ltd from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
4.72 -
US
5.67 -
US
- -
CN
16.40 -
US
9.55 -
US